COLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Collegium Pharmaceutical looks like a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has clear fundamental momentum, a strong earnings beat, positive revenue and profit growth, and a fresh catalyst from the AZSTARYS acquisition that extends growth visibility. The current price is near resistance but still within a constructive breakout setup, and the market tone is supportive enough to justify buying now rather than waiting.
COLL is in a short-term uptrend. The MACD histogram is positive and expanding, which supports bullish momentum. RSI_6 is 91.691, which is overbought and suggests the stock has already run sharply, but it also confirms strong demand. Moving averages are converging, indicating the move may be transitioning from consolidation to a new upward leg. Key levels show support at 35.338 and 32.394, with resistance at 38.283 and 40.102. Since the stock closed at 40.00, it is testing the upper resistance zone and has broken above the prior close materially. For an impatient investor, this is still a valid entry because momentum is strong and the trend is positive.
["Q1 2026 earnings beat: non-GAAP EPS of $1.76 topped estimates by $0.24.", "Revenue grew 8.8% to 193.5M year over year.", "Net income rose sharply to 14.49M from 2.42M last year.", "Gross margin improved to 60.59%, showing stronger profitability.", "Acquisition of AZSTARYS for $650M adds ADHD growth potential and extends revenue visibility through patent protection until 2037.", "Analyst sentiment is positive, with Truist raising its target to $58 and reiterating Buy.", "Price momentum is strong and supported by bullish MACD behavior.", "Similar candlestick pattern analysis suggests upside probability over the next day, week, and month."]
["RSI is deeply overbought, which means the stock has already moved fast.", "Insiders are selling, with selling activity increasing 145.95% over the last month.", "Hedge funds are neutral, so institutional conviction is not strongly expanding.", "Price is pressing into resistance near 40.102, so near-term upside may be less linear after the recent surge."]
Latest quarter: Q1 2026. Collegium delivered strong quarterly results with revenue up 8.87% year over year to 193.52M. Net income jumped 499.75% year over year to 14.50M, EPS rose 414.29% year over year, and gross margin improved to 60.59%. The quarter shows accelerating growth and meaningful operating leverage, which is favorable for a long-term investor.
Analyst sentiment is positive and improving. Truist raised its price target to $58 from $55 and kept a Buy rating, citing Jornay momentum and durability in the pain portfolio. Wall Street pros appear constructive on the stock’s growth story and pipeline durability, while the main con is that the stock has already rallied quickly and some insider selling is occurring.
